You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR ABILIFY


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ABILIFY

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00044655 ↗ Switching Medication to Treat Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 2001-07-01 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00044655 ↗ Switching Medication to Treat Schizophrenia Completed Icahn School of Medicine at Mount Sinai Phase 4 2001-07-01 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00080314 ↗ Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode Completed Otsuka America Pharmaceutical Phase 3 2004-01-01 The purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression.
NCT00080314 ↗ Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode Completed Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 3 2004-01-01 The purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression.
NCT00080327 ↗ Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia Completed Otsuka America Pharmaceutical Phase 4 2003-11-01 A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
NCT00080327 ↗ Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia Completed Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 4 2003-11-01 A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
NCT00082199 ↗ Study of Aripiprazole in Subjects With Alcoholism Completed Otsuka America Pharmaceutical Phase 4 2004-04-01 The purpose of this clinical research study is to learn whether subjects treated with aripiprazole are able to abstain from alcohol use for a greater number of days than subjects treated with placebo. The safety of using aripiprazole will also be studied.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ABILIFY

Condition Name

Condition Name for ABILIFY
Intervention Trials
Schizophrenia 61
Bipolar Disorder 25
Major Depressive Disorder 16
Schizoaffective Disorder 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ABILIFY
Intervention Trials
Schizophrenia 63
Disease 52
Bipolar Disorder 28
Psychotic Disorders 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ABILIFY

Trials by Country

Trials by Country for ABILIFY
Location Trials
United States 592
Canada 26
United Kingdom 21
Korea, Republic of 18
South Africa 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ABILIFY
Location Trials
California 41
New York 40
Texas 33
Ohio 29
Florida 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ABILIFY

Clinical Trial Phase

Clinical Trial Phase for ABILIFY
Clinical Trial Phase Trials
Phase 4 67
Phase 3 44
Phase 2/Phase 3 1
[disabled in preview] 43
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ABILIFY
Clinical Trial Phase Trials
Completed 123
Terminated 15
Unknown status 7
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ABILIFY

Sponsor Name

Sponsor Name for ABILIFY
Sponsor Trials
Otsuka Pharmaceutical Development & Commercialization, Inc. 41
Bristol-Myers Squibb 30
Otsuka America Pharmaceutical 28
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ABILIFY
Sponsor Trials
Other 140
Industry 128
NIH 22
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.